Rhythm Pharmaceuticals (RYTM) Non-Current Deffered Revenue (2016 - 2024)

Rhythm Pharmaceuticals (RYTM) has 8 years of Non-Current Deffered Revenue data on file, last reported at $109.2 million in Q3 2024.

• On a quarterly basis, Non-Current Deffered Revenue rose 4.34% year-over-year to $109.2 million in Q3 2024; TTM through Sep 2024 was $109.2 million, a 4.34% increase from a year earlier, with the FY2023 full-year figure at $106.1 million, up 40.01% from the prior year.
• Non-Current Deffered Revenue for Q3 2024 stood at $109.2 million, up from $108.4 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for RYTM reached as high as $109.2 million in Q3 2024 and fell as low as $3.0 million in Q1 2020.
• Historically, Non-Current Deffered Revenue has averaged $85.7 million across 4 years, with a median of $104.7 million in 2023.
• Across the five-year window, Non-Current Deffered Revenue soared 40.01% in 2023 and grew 4.34% in 2024, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $3.0 million in 2020, then soared by 2462.01% to $75.8 million in 2022, then surged by 40.01% to $106.1 million in 2023, then gained by 2.92% to $109.2 million in 2024.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $109.2 million in Q3 2024, $108.4 million in Q2 2024, and $107.4 million in Q1 2024.